

DOCKET NO: ISIS0166-100 (RTS-0147)

PATENT

In the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Please amend claims 1, 5, 7, and 9 and cancel claims 4, 6, and 8 without prejudice to their presentation in another application.

1. (currently amended) A compound 8 to 50 nucleobases in length targeted to nucleobases 652 through 772 of a coding region of a nucleic acid molecule encoding human Phospholipid scramblase I (SEQ ID NO: 3), wherein said compound comprises a modification to at least one internucleoside linkage, sugar moiety, or nucleobase, and wherein said compound specifically hybridizes with said region and inhibits the expression of human Phospholipid scramblase I.
2. (original) The compound of claim 1 which is an antisense oligonucleotide.
- 3-4. (canceled).
5. (currently amended) The compound of ~~claim 4~~ claim 2 wherein the modified internucleoside linkage is a phosphorothioate linkage.
6. (canceled).
7. (currently amended) The compound of ~~claim 6~~ claim 2 wherein the modified sugar moiety is a 2'-o-methoxyethyl sugar moiety.
8. (canceled).
9. (currently amended) The compound of ~~claim 8~~ claim 2 wherein the modified nucleobase is a 5-methylcytosine.

DOCKET NO: ISIS0166-100 (RTS-0147)

PATENT

10. (original) The compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide.
11. (canceled).
12. (original) A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or diluent.
13. (original) The composition of claim 12 further comprising a colloidal dispersion system.
14. (original) The composition of claim 12 wherein the compound is an antisense oligonucleotide.
15. (previously presented) A method of inhibiting the expression of Phospholipid scramblase I in cells or tissues comprising contacting said cells or tissues with the antisense compound of claim 1 so that expression of Phospholipid scramblase I is inhibited.
- 16-20. (cancelled).